

Task Force on Repurposing of Drugs (TFORD) for COVID-19

Patent status in India: by GNANLEX

Sarilumab

A. Active patents

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	High Affinity Antibodies To Human Il-6 Receptor	Regeneron Pharmaceuticals, Inc.	Grant no: IN273688 Priority date: 02/06/2006 Grant date: 23/06/2016 Expected expiry date: 01/06/2027 Form 27: Patent not worked in India	Sarilumab API	Patent Barrier upto 01/06/2027. Licensing option may be explored

B. Pending applications

S.no.	Title	Assignee	Application details	Type of patent	Remarks
1.	Continuous multistep process for purifying antibodies	Sanofi	App no: 3738/KOLNP/2015 Filing/Priority date: 12/11/2015 Status: Reply to FER was submitted on 12/08/2019	Purification Process	Patent Barrier if granted. Licensing option may be explored
2.	Liquid protein formulations containing viscosity lowering agents	Eagle Biologics, Inc.	App no: IN201617011562 Filing/Priority date: 11/09/2013 Status: RFE was filed on 07/09/2017	Formulation	Patent Barrier if granted. However, may be worked around
3.	Liquid protein formulations containing ionic liquids	Eagle Biologics, Inc.	App no: IN201918052132 Filing/Priority date: 11/09/2013 Status: RFE was filed on 16/12/2019	Formulation	Patent Barrier if granted. However, may be worked around
4.	Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same	1. Sanofi Biotechnology 2. Regeneron Pharmaceuticals, Inc.	App no: IN201817020471 Filing/Priority date: 03/11/2015 Status: RFE was filed on 30/09/2019	Composition and Method	Patent Barrier if granted. Licensing option may be explored

C. Expired/Lapsed applications – None

Disclaimer:

Search results are up to 21st May 2020

GNANLex's Opinion / Report as hereinabove is to the best of our knowledge, true and accurate as of the date compiled based on available information. However, no guarantee is made as to its accuracy, reliability or completeness. The final user is expected to assume sole liability for any patent infringement that occurs by following our recommendations or using the information given. Before using, user should determine the suitability of the information for his intended use. The risk and liability, if any, in connection therewith, is solely that of the user.

Commissioned by

